Table 2.

Pilot placebo-controlled studies of SGLT2 inhibitors as an adjunct therapy to insulin in youth with type 1 diabetes

Study	SGLT2 inhibitor (mg)	Insulin dosea (%)	Urinary glucose excretiona (%)	Time in rangea 3.9–10.0 mmol/L (70–180 mg/dL) (%)	β-Hydroxybutyrate level (mmol/L)
					SGLT2 inhibitor	placebo
Biester et al. [45]	Dapagliflozin 10	−13.6	+610	−	0.17	0.11
DAPADream [46]	Dapagliflozin 20	−22	+212	+18	0.29	0.16

SGLT2, sodium-glucose co-transporter-2.

^aRelative to placebo.